SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Files An 8-K Financial Statements and Exhibits

SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.

Story continues below


SUNESIS PHARMACEUTICALS INC Exhibit
EX-99.1 2 snss-ex991_6.htm EX-99.1 PRESS RELEASE DATED DECEMBER 2,…
To view the full exhibit click here

About SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

An ad to help with our costs